ClinicalTrials.gg
CompletedNCT01710007Updated Jul 17, 2023Results posted

Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia

A Phase 3 interventional study of 1PC002 and Lipitor in Hypercholesterolemia, sponsored by Orient Pharma Co., Ltd.. Completed at 8 sites in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by Orient Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing pitavastatin in Hypercholesterolemia — none open to participants now, none under way, none of them phase 3. pitavastatin · Hypercholesterolemia.

Enrollment
9th of 19
202 · median 200
Started
2011
with 1 other
Phase 3
9 of 19
none open now
Registered
17th of 19
by date
Lead sponsor
1 of 19
Orient Pharma Co., Ltd.

Among the 19 studies testing pitavastatin in Hypercholesterolemia, this one is the 9th largest by enrollment, is one of 2 that started in 2011, is one of 9 in phase 3, and was the 17th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

None of the 19 studies testing pitavastatin in Hypercholesterolemia is open now. The open studies under Hypercholesterolemia, anywhere →

About pitavastatin

pitavastatin: first FDA approval 2009 (LIVALO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing pitavastatin in Hypercholesterolemia as a file.
02

Study summary

1PC002 is a newly developed synthetic and highly potent HMG-CoA reductase inhibitor. Its active compound, pitavastatin has recently been approved by US FDA for indications of primary hypercholesterolemia and combined dyslipidaemia. It exhibits unique pharmacokinetic properties. Unlike atorvastatin which is metabolized by CYP3A4, metabolism of 1PC002 does not depend on CYP3A4. This multi-center study is conducted to confirm the efficacy and safety of 1PC002 administered for 12 weeks is non-inferior to atorvastatin.

Read the detailed description

This is a prospective, active-controlled, double-blind, randomized, parallel, and multi-center study. To target 150 evaluable subjects, approximately 200 Taiwanese patients with primary hypercholesterolemia or combined dyslipidemia will be enrolled in this study.

After providing the written inform consent, patients will undergo a complete physical examination, vital sign (brachial BP / HR), medical history, and lab assessment, including fasting serum LDL-C, TC, HDL-C, TG, and non-HDL. They should not take any hypolipidemic drugs for at least 4 weeks prior to initiation of study treatment. All eligible subjects will be randomized into 2 groups in a 1:1 ratio to receive either 2 mg 1PC002 or 10 mg atorvastatin once daily for 12 weeks.

  • Study Group: 1PC002 1 cap. q.d. p.o.
  • Control Group: Atorvastatin 1 cap. q.d. p.o.

After entering the baseline visit, lipid profiles (including fasting serum LDL-C, TC, HDL-C, TG, non-HDL, Apo A1, Apo B and Apo B / Apo A1 ratio), hs-CRP, eGFR, spot urinary albumin / creatinine ratio (ACR) and central BP values will be obtained at baseline, Week 4 and Week 12 for evaluating the effectiveness of study drugs and for any possible changes in laboratory data. Non-HDL value will be calculated by subtracting HDL-C from TC. Moreover, serum Cystatin C, another biomarker of renal function, will also be assessed at baseline and Week 12.

For monitoring the safety, biochemical and hematological assessment will be performed at baseline, Week 4 and 12. Additional liver function and CK test will be conducted at Week 8. The occurring AE(s) and SAE will be followed until resolution or the event is considered stable.

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • HMG-CoA reductase inhibitors
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females or males aged between 20 and 80 years.
  2. Subjects who meet All of the following diagnosis at screening visit:

    • Primary hypercholesterolemia or combined dyslipidemia
    • TC ≥ 220 mg/dL or LDL-C ≥ 130 mg/dL
    • TG \< 400 mg/dL
  3. Subjects who is willing and able to provide ICF.

Exclusion criteria

Exclusion Criteria:

  1. Females who are pregnant, breast-feeding or intent to be pregnant during study period, or those of not using effective .
  2. Subject with documented homozygous familial hypercholesterolemia.
  3. Subject with documented .
  4. Subject with documented hypothyroidism and inadequate treatment judged by investigator.
  5. Subjects with unstable cardiovascular disease (CVD) prior to randomization.
  6. Subjects with hepatic or biliary disorders, such as acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer and jaundice.
  7. Any condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs.
  8. Subjects with the following lab data at screening visit:

    • serum creatine kinase (CK) > 5 x (ULN)
    • or AST of > 3 x ULN
    • serum creatinine ≥ 1.5 mg/dL
    • > 8.0%
  9. Subject with the following past histories:

    • to statins or any other ingredients of study drugs
    • resistant to statins treatment
  10. Use of any lipid-lowering agents within 4 weeks prior to the initiation of study treatment.
  11. Use of any product within 4 weeks prior to screening.
  12. Any unstable concomitant disease or clinical condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk to participate in the study or confounds the ability to interpret data from the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    1PC002

    2 mg 1PC002 once daily for 12 weeks.

    Drug: 1PC002

  • Active comparator
    Lipitor

    10 mg atorvastatin once daily for 12 weeks.

    Drug: Lipitor

Interventions

  • Drug1PC002

    Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.

    Also known as: Pitavastatin

  • Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.

    Also known as: Atorvastatin

06

What researchers measure

Primary outcomes

  1. The Percentage Change From Baseline in LDL-C Level at Week 12.

    The study aimed to test that the efficacy of 1PC002 group was non-inferior to Atorvastatin group in percent change from baseline of LDL-C level at Week 12.

    Time frame: 12 weeks

Secondary outcomes

  1. LDL-C

    Percent change from baseline in LDL-C level at Week 4

    Time frame: week 4

  2. HDL-C

    Percent change from baseline in HDL-C level at Week 4

    Time frame: week 4

  3. Triglyceride

    Percent change from baseline in TG level at Week 4

    Time frame: week 4

07

Results

Posted Jul 17, 2023

Participant flow

Participant flow — Overall Study
Milestone1PC002Lipitor
Started10399
Completed8781
Not completed1618

Outcome measures

PrimaryThe Percentage Change From Baseline in LDL-C Level at Week 12.

The study aimed to test that the efficacy of 1PC002 group was non-inferior to Atorvastatin group in percent change from baseline of LDL-C level at Week 12.

Time frame:
12 weeks
Reported as:
Mean · Percent change from baseline
The Percentage Change From Baseline in LDL-C Level at Week 12.
Percent change from baselineLipitor1PC002
The Percentage Change From Baseline in LDL-C Level at Week 12.-42.89 ± 12.80-37.43 ± 17.97
SecondaryLDL-C

Percent change from baseline in LDL-C level at Week 4

Time frame:
week 4
Reported as:
Mean · Percent change from baseline
LDL-C
Percent change from baseline1PC002Lipitor
LDL-C-39.01 ± 13.04-40.07 ± 12.18
SecondaryHDL-C

Percent change from baseline in HDL-C level at Week 4

Time frame:
week 4
Reported as:
Mean · Percent change from baseline
HDL-C
Percent change from baseline1PC002Lipitor
HDL-C0.06 ± 10.49-1.64 ± 11.01
SecondaryTriglyceride

Percent change from baseline in TG level at Week 4

Time frame:
week 4
Reported as:
Mean · Percent change from baseline
Triglyceride
Percent change from baseline1PC002Lipitor
Triglyceride-18.75 ± 26.9-19.5 ± 25.5

Adverse events

Collected over 12-16 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1PC002—3/103 (2.9%)58/103 (56.3%)
Lipitor—1/99 (1%)55/99 (55.6%)
Most frequent serious events
Most frequent serious events
Event1PC002Lipitor
Congestive heart failureCardiac disorders0/1031/99
Cellulitis,right handInfections and infestations1/1030/99
Rheumatic heart disease with Moderate Calcified Mitral stenosisCardiac disorders1/1030/99
Urinary tract infectionsInfections and infestations1/1030/99
Most frequent other events
Showing 10 of 83
Most frequent other events
Event1PC002Lipitor
Upper respiratory tract infectionInfections and infestations11/1039/99
Blood creatine phosphokinaseInvestigations9/1036/99
MyalgiaMusculoskeletal and connective tissue disorders1/1036/99
InsomniaPsychiatric disorders1/1034/99
Back painMusculoskeletal and connective tissue disorders4/1031/99
DizzinessNervous system disorders4/1031/99
MicroalbuminuriaRenal and urinary disorders1/1033/99
PruritusSkin and subcutaneous tissue disorders2/1033/99
Oedema peripheralGeneral disorders3/1031/99
Hepatic enzyme increasedInvestigations3/1030/99

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)1PC002LipitorTotal
<=18 years000
Between 18 and 65 years8793180
>=65 years16622
Age, Continuous
Age, Continuous(years)1PC002LipitorTotal
Mean55.36 ± 10.5057.90 ± 8.8056.60 ± 9.76
Sex: Female, Male
Sex: Female, Male(Participants)1PC002LipitorTotal
Female6057117
Male434285
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1PC002LipitorTotal
Hispanic or Latino000
Not Hispanic or Latino10399202
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)1PC002LipitorTotal
Taiwan103.99202
08

Study locations

8 sites
  • Buddhist Taipei TzuChi General Hospital
    New Taipei City, 23142, Taiwan
  • Cardinal Tien Hospital
    New Taipei City, 231, Taiwan
  • Taipei Medical University - Shuang Ho Hospital
    New Taipei City, 23561, Taiwan
  • Taichung Veterans General Hospital
    Taichung City, 40705, Taiwan
  • Taipei Veterans General Hospital
    Taipei City, 11217, Taiwan
  • Cheng Hsin General Hospital
    Taipei City, 112, Taiwan
  • Tri-Service General Hospital
    Taipei City, 114, Taiwan
  • Chang Gung Medical Foundation- LinKuo Branch
    Taoyuan City, 333, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Sep 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2023, 10 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 18, 2012
Start
Nov 2011
Primary completionActual
Sep 2012
CompletionActual
Nov 2012
Results first posted
Jul 17, 2023
Last update
Jul 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01710007
Lead sponsor
Orient Pharma Co., Ltd.
Collaborators
Orient Europharma Co., Ltd.
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Nov 2011
Primary completion
Sep 2012
Completion
Nov 2012
Results posted
Jul 17, 2023
Last update
Jul 17, 2023

Study contacts

Chiau-Suong Liau
principal investigator · Buddhist Taipei TzuChi General Hospital
Ming-Shien Wen
principal investigator · Chang Gung Medical Foundation- LinKuo Branch
Wen-Pin Huang
principal investigator · Cheng-Hsin General Hospital
Dee Pei
principal investigator · Cardinal Tien Hospital
Wei-Shiang Lin
principal investigator · Tri-Service General Hospital
Huey-Herng Sheu
principal investigator · Taichung Veterans General Hospital
Chen-Huan Chen
principal investigator · Taipei Veterans General Hospital, Taiwan
Ju-Chi Liu
principal investigator · Taipei Medical University Shuang Ho Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion